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Abstract
Background:  Inflammation and oxidative stress are both involved in the pathogenesis of
Alzheimer disease and have been shown to be reciprocally linked. One group of molecules that
have been directly associated with inflammation and the production of free radicals are the
prostaglandin 13,14-dihydro 15-keto PGF2α and the isoprostane 8-iso-PGF2α.
Results: To further delineate the role of inflammatory and oxidative parameters in Alzheimer
disease, in this study we evaluated the amount and localization of 13,14-dihydro 15-keto PGF2α and
8-iso-PGF2α in hippocampal post mortem tissue samples from age-matched Alzheimer disease and
control patients. Our results demonstrate increased levels of 13,14-dihydro 15-keto PGF2α and 8-
iso-PGF2α in the hippocampal pyramidal neurons of Alzheimer disease patients when compared to
control patients.
Conclusion: These data not only support the shared mechanistic involvement of free radical
damage and inflammation in Alzheimer disease, but also indicate that multiple pathogenic "hits" are
likely necessary for both the development and propagation of Alzheimer disease.
Background
Alzheimer disease (AD) is the leading cause of senile
dementia, with a prevalence that is directly related to age
[1]. Over 4 million individuals are currently affected with
the disease in the United States alone and this number is
projected to increase to 14 million by 2050 [2]. At the
present time, therapeutic management of the disease is
primarily focused on palliative treatment of the symp-
toms rather than forestalling the progression of the dis-
ease [3] and the major obstacle in designing a rationale for
therapeutic targets is our incomplete understanding of
pathogenesis. To this end, it is imperative that the mecha-
nistic hallmarks of this disease are established.
The tight association between aging and AD has led the
field to propose oxidative stress as a major mechanism
responsible for the onset and progression of AD [4]. Phys-
iologically, the production of reactive oxygen species
(ROS) is found in all aerobic organisms and arises from
the secondary production of superoxide, hydrogen perox-
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ide and the reaction of superoxide with nitric oxide (per-
oxynitrite) during metabolic and extra-metabolic
processes of all cells. In AD, the excess formation of ROS
is evident by signature reactions with critical biological
molecules yielding damage to every category of biomacro-
molecules: sugars, lipids, proteins and nucleic acids [4].
That such oxidative damage occurs as one of the earliest
aberrations in the disease indicates a major role of free
radical damage in both etiology and pathogenesis.
In addition to direct oxidation damage of cellular macro-
molecules, free radical formation can also lead to damage
indirectly by activating other harmful mechanisms such as
inflammation [5]. In this regard, oxidative stress and
inflammation are reciprocally linked such that inflamma-
tory processes lead to increases in ROS production [6] and
vice versa [7]. Given this interdependence, it is perhaps
not surprising that ROS and inflammation can both be
attenuated by individually targeted treatments, i.e., anti-
oxidant or non-steroidal anti-inflammatory drug treat-
ment [6,8,9].
Of note in this regard, epidemiological studies indicate a
reduced risk of AD among users of anti-inflammatory
drugs. Animal studies demonstrate that the capacity of
non-steroidal anti-inflammatory drugs (NSAIDs) is to
reduce the amount of plaque formation in mouse models
of the disease. NSAIDs work mainly through the inhibi-
tion of cyclooxygenase, which is a critical component of
the inflammatory response [10]. Therefore, anti-inflam-
matory drugs such as NSAIDs have become the focus of
several new treatment strategies [11,12].
Like oxidative stress, inflammatory processes have been
associated with AD and thought to play a major role in its
onset and progression. In this regard, cytokines, such as
interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis
factor  α (TNF-α) and transforming growth factor beta
(TGF-β) are all affected and likely contribute to the
inflammatory activation of microglia and astroglia [13].
One group of novel molecules that establish the link
between inflammation and oxidative stress are prostag-
landins and isoprostanes, respectively [14,15]. Prostag-
landins are a group of 20-carbon containing hormone-
like fatty acid derivatives that are produced by catalyzed
cyclooxygenase of the arachidonic acid and localized to
various tissues in the body [16]. Prostaglandins are impor-
tant mediators of the inflammatory process [17,18] and
13,14-dihydro 15-keto PGF2α a major metabolite of pros-
taglandin F2α (PGF2α), is shown to be a potent indicator of
in vivo cyclooxygenase (COX)-mediated inflammatory
processes [19-22]. On the other hand, F2-isoprostanes,
prostaglandin-like novel compounds are formed during
free-radical catalyzed, non-enzymatic peroxidation of ara-
chidonic acid [23] and, as such, considered to be reliable
indicators of oxidative stress in vivo [14,22,24].
With regard to AD, some studies have shown increased
F2-isoprostane levels in plasma or urine of AD patients
compared to age-matched controls [25-27], however
these findings remain controversial [28-30]. In addition,
increased CSF levels of F2-isoprostanes have also been
shown in AD patients [25,28,31-33], which, importantly,
can be suppressed by antioxidant treatment [34]. While
levels within the brain have been found to be increased in
regions vulnerable to the disease [35,36], controversy
remains as to localization (i.e., glia or disease-vulnerable
neurons) and whether increased F2-isoprostane levels in
AD are associated with the progression of the disease or
rather are simply markers of increased gliosis [30]. In an
attempt to clarify this controversy and accurately localize
the presence of both PGF2α and F2-isoprostanes, we used
an immunohistochemical method to examine both the
levels and the subcellular localization of PGF2α and F2-iso-
prostanes in the AD brain.
Results
Detailed microscopic localization of 8-iso-PGF2α and 13,
14-dihydro 15-keto PGF2α in the AD cases revealed strong
labeling of the cytoplasm of neurons, when compared to
age-matched control cases (Figure 1). Neuronal popula-
tions principally affected were large pyramidal neurons of
the hippocampal formation (CA-1, CA-2, and CA-3/4),
subiculum, pre-α layer of the entorhinal cortex, and cere-
bral neocortex. While neurons affected by neurofibrillary
pathology showed labeling with both antibodies, there
was no predilection for pathologically altered neurons, as
the majority of the labeling occurred in the perikaryal
cytoplasm of morphologically normal pyramidal neu-
rons. Dystrophic neurites and neuropil threads were not
observed with 13,14-dihydro 15-keto PGF2α and 8-iso-
PGF2α  antibodies. No labeling of neuritic plaques or
parenchymal amyloid-β deposits could be discerned. In
addition to neuronal immunoreactivity, immunolabeling
of reactive astrocytes, generally in parallel with the perinu-
clear accumulations of glial filaments, was noted diffusely
in some sections. Blood vessels, ependymal cells, and
choroid plexus epithelium showed no significant immu-
noreactivity. Demonstrating the specificities of our find-
ings, antibodies directed against porcine-thyroglobulin
linked 13,14-dihydro 15-keto PGF2α  and 8-iso-PGF2α
revealed very similar staining patterns of increased neuro-
nal as well as glial cells in AD cases. Moreover, omission
of the primary antibodies completely abolished immuno-
reactivity (data not shown).
Quantification of the relative densities of pyramidal neu-
rons stained revealed a statistically significant increase in
the immunoreactivities for 8-iso-PGF2α (p < 0.01) andMolecular Neurodegeneration 2007, 2:2 http://www.molecularneurodegeneration.com/content/2/1/2
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Isoprostanes localization in AD and control brain Figure 1
Isoprostanes localization in AD and control brain. In adjacent serial sections of hippocampus of AD cases, neurons are 
intensely labeled with antisera against 13,14-dihydro 15-keto PGF2α (A) and 8-iso-PGF2α (C). AT8 recognizes NFT in the same 
field (E). In adjacent serial sections from an age-matched control, neuronal levels of 13,14-dihydro 15-keto PGF2α (B) and 8-iso-
PGF2α (D) are significantly lower. Only a few NFT recognized by AT8 are present in the control. (*) marks landmark vessels in 
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PGF2α metabolite (p < 0.001) in AD cases (Figure 2A). In
the same three fields on adjacent serial sections stained for
phosphorylated tau, the number of immunostained neu-
rofibrillary tangles (NFT) was quantified. In the AD cases,
the number of NFT within the three fields analyzed
ranged from 31–293 NFT, mean of 121. Eight of the 10
age-matched control cases contained small numbers of
AT8-positive NFT, ranging from 3–43 in the fields ana-
lyzed, mean of 20.3. Relative neuronal density of 8-iso-
PGF2α or PGF2α metabolite in the AD cases showed no cor-
relation with the number of NFT (r = 0.12), while the con-
trol cases showed a significant positive correlation (r =
.68; p < 0.05) of NFT numbers with 8-iso-PGF2α (Fig 2B).
No significant correlation was noted between levels of
13,14-dihydro 15-keto PGF2α and 8-iso-PGF2α with age in
either the control or AD cases.
Discussion
The data presented in this study shows both PGF2α and F2-
isoprostanes are increased in hippocampal tissue col-
lected from AD patients compared to non-AD patients,
indicating that brain inflammation and oxidative stress
are significantly higher in AD compared to the aged-
matched controls. This study is the first of its kind to
report an increased level of a prostaglandin F2α-metabo-
lite, which corresponds to the level of the COX-mediated
primary prostaglandin F2α, in the brains of individuals
affected by AD. This data certainly augments the work of
Ho et al, who carefully characterized the appearance and
progression of neuronal accumulation of COX-2 as both
a function of clinical course of the disease as well as
within different neuronal populations of the hippocam-
pus [37]. Their findings highlight the COX-2 involvement
early in the disease course which provides a reasonable
and prudent target for therapeutics such as NSAIDS. This
is extremely relevant to the current work on prostagland-
ins, whose appearance coincides with the cellular location
and development of pathology as seen with COX-2.
Prostaglandins are well-known mediators of inflamma-
tion [17]. 15-Keto-dihydro-PGF2α, a metabolite of bioac-
tive PGF2α metabolized through 13,14-dihydro 15-keto
PGF2α dehydrogenases in most of the tissues in the body
is a potent indicator of in vivo inflammatory processes
[19-22]. Thus, the results from this study suggest a local
ongoing COX-related inflammatory process among
patients with AD, which possibly plays a major role in the
onset or progression of the disease. In addition, PGF2α is
shown to be a potent vasoconstrictive compound [38]
which also may play a role in the progression of AD in
which vascular degeneration is a characteristic [4]. Nota-
bly, amyloid-β itself can act as a pro-inflammatory agent
causing the activation of many of the inflammatory com-
ponents, including glial activation [39,40] and, in some-
what of a feedforward manner, cyclooxygenases
potentiate the generation of amyloid-β [41]. However, it
is important to note that our findings revealed little corre-
lation between amyloid and 13,14-dihydro 15-keto
PGF2α and 8-iso-PGF2α. Similarly, while no correlation
was found with phosphorylated tau among the AD cases,
a positive correlation was seen among the controls, indi-
cating the inflammatory response as an early change.
Clinical data on the mental status of the control cases used
in this study was not available, therefore further analysis
using clinically followed cases of mild cognitive impair-
ment would be required to faithfully answer this ques-
tion. These findings are not only consistent with findings
of other oxidative adducts [42,43], but also emphasize the
often different properties of amyloid-β and phosphor-
ylated tau in vivo compared to in vitro [44,45].
Another novel finding in this study is that the levels of F2-
isoprostanes are increased in hippocampal sections from
patients with AD as compared to the control subjects.
These findings are in accordance with previous mass spec-
trometry studies demonstrating increased levels of F2-iso-
prostanes in the AD brain [46]. Our study has now shown
the specific localization of these proteins in the AD brain
demonstrating that these adducts strikingly localize to
vulnerable neurons in the disease as well as other cellular
types like glia, often associated with inflammatory
responses. F2-isoprostanes are now regarded as one of the
most reliable indicators of oxidative stress in vivo [15,47].
Elevated level of isoprostanes has been shown in CSF and
brain tissue previously [35,48], however, there are contro-
versies regarding the levels of isoprostanes in the plasma
or urine [15]. One study describes higher levels of isopros-
tanes in the plasma and urine [25], while others do not
[28,29] The accumulation of both PGF2α and F2-isopros-
tanes in cerebral tissues collected from AD are an unique
finding since both of these compounds possess extremely
short half-lives [16,49,50]. In this regard, elevations of
these compounds are seen only for a short period of time
in experimental acute inflammation protocols (e.g., septic
shock) following cardiac arrest or cardio pulmonary
bypass surgery, which rapidly decrease to the initial basal
levels [19,21,51]. Nevertheless, a more persistent rise of
basal levels of these compounds is observed during
chronic inflammation such as in various rheumatic dis-
eases and type 2 diabetes [15]. Therefore, as previously
suggested [52], the levels of oxidative stress are likely low
and chronic in nature.
Notably, and in addition to being excellent markers of
inflammation, both PGF2α and F2-isoprostanes (mainly 8-
iso-PGF2α) possess independent bioactive properties. That
no age related increase was found in either the normal or
disease tissue suggests a more direct role in disease patho-
genesis. In this regard, PGF2α and F2-isoprostanes (mainly
8-iso-PGF2α) are potent vasoconstrictive agents, andMolecular Neurodegeneration 2007, 2:2 http://www.molecularneurodegeneration.com/content/2/1/2
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Quantification of neuronal levels of isoprostanes Figure 2
Quantification of neuronal levels of isoprostanes. A. Computer assisted image analysis reveals pyramidal neurons from cases of 
AD (n = 10) reveal significantly higher levels of 8-iso-PGF2α (p < 0.01) and13,14-dihydro 15-keto PGF2α (p < 0.001) than aged 
controls (n = 10). Mann-Whitney U-test. Data shown expresses mean +/- SEM. B. In the aged control cases, neuronal levels of 
8-iso-PGF2α are significantly correlated with the numbers of AT8-positive NFT.
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PGF2α is a well known mediator of pain and inflamma-
tion [17]. Further it has recently been shown that 8-iso-
PGF2α can induce PGF2α release and thereby inflammatory
responses in rabbits [15]. Therefore, the accumulation of
PGF2α and F2-isoprostanes in the cerebral tissues not only
indicates the presence of massive inflammation in the AD
brain but also highlights the impact that these com-
pounds could have independent bioactive entities, where
a chronic accumulation of these compounds in the brain
could further worsen the status of inflammation and oxi-
dative stress and thus the pathophysiology of the disease.
These latter findings together with the current findings of
in situ localization of F2-isoprostanes in the hippocampal
or cortical tissue samples from AD patients further sup-
ports the notion that locally involved oxidative stress
together with the inflammatory response is possibly one
of the major mechanistic hallmarks of AD and therefore
represent therapeutic intervention points of great poten-
tial. However, despite the apparent effectiveness for
NSAIDs, which are COX inhibitors, and antioxidants on
preventing the risk of developing AD consistently
reported in epidemiology studies [53,54], clinical trials
with these drugs demonstrate little to no effect in AD
patients [55]. These findings highlight the importance of
early interruption of pathogenic processes, consistent
with our finding of a positive correlation between neuro-
nal 8-iso-PGF2α and NFT numbers in control cases but not
in AD cases.
In conclusion, this study presents an accumulation of
both prostaglandins and isoprostanes in the brain tissues
of patients with AD which further advocates for impor-
tance of inflammation and oxidative stress in this disease
and treatment strategies that counteract inflammatory
processes and oxidative stress simultaneously.
Methods
Tissue
Hippocampal and cortical tissue samples were obtained
post mortem from patients with histopathologically con-
firmed AD (n = 21, ages 61–96 years, mean = 80.8 years).
Control cases used in this study included 3 young (ages
17, 23, and 43 years) and 13 aged-matched controls (ages
60–91 years, mean 72.9 years) with similar post mortem
intervals (AD: 3–37 hr, mean 14.3 hour; controls: 3–48
hr, mean 19.1 hr). All cases were categorized based on
clinical and pathological criteria established by CERAD
and NIA consensus panel [56,57]. From the clinical
reports available to us, we found no obvious differences in
agonal status or other potential confounders between the
groups. Tissue was fixed in methacarn (methanol: chloro-
form: acetic acid; 6: 3: 1 v/v/v) at 4°C overnight. Follow-
ing fixation, tissue was dehydrated through ascending
ethanol, embedded in paraffin, and 6-μm sections were
placed on silane-coated slides (Sigma, St. Louis, MO,
USA).
Immunocytochemistry
Tissue sections were de-paraffinized in xylene, hydrated
through descending ethanol, and endogenous peroxidase
activity quenched by a 30 min incubation in 3% hydrogen
peroxide in methanol. Non-specific binding sites were
blocked by a 30 min incubation in 10% normal goat
serum. Tissue sections were immunostained using the per-
oxidase/anti-peroxidase method with 3-3'-diaminobenzi-
dine as co-substrate as previously described [5].
Antibodies used were: 1) rabbit polyclonal antibody to
free 13,14-dihydro 15-keto PGF2α [22]; 2) rabbit polyclo-
nal antibody to free 8-iso-PGF2α [58]; 3) rabbit polyclonal
antibody to free 8-iso-PGF2α conjugated to porcine thy-
roglobulin (Assay Designs, MI); and 4) rabbit polyclonal
antibody to free 13, 14-dihydro 15-keto PGF2α (Cayman
Chemical, MI). Sections were also immunostained with a
monoclonal mouse antibody AT8, which recognizes
phosphorylated tau (Ser202/Thr205) (Pierce, Rockford,
IL) to identify the location of pathological structures.
Control experiments included omission of primary antis-
era.
Quantification
Quantification of 13, 14-dihydro 15-keto PGF2α and 8-
iso-PGF2α  protein immunoreactivity was performed as
previously described [43]. The cases used included 10 AD
(ages 65–87 years) and 10 age-matched controls (ages
67–82 years) that were randomly selected and stained
with the same antisera [22,58] at the same time. Digital
images were taken with an Axiocam camera (KS300, Zeiss,
Munchen-Hallbergmoss, Germany) and compatible
quantification software (Axiovision, Carl Zeiss Vision
GmbH, Munchen-Hallbergmoss, Germany) used to deter-
mine the mean staining intensity of pyramidal neurons in
the CA1/CA2 region of the hippocampus. Briefly, using
the 20× objective, 3 fields were selected and the software
outlined the immunostained structures and measured the
intensity. The intensity of all unstained areas within each
fields are determined as the background levels. In those
cases where neuronal staining was at the background level
and the software unable to delineate the cell bodies, all
pyramidal neurons within each field, where nuclei were
visible were outlined manually and measured as above.
Mean neuronal intensities for each case were determined
and because the n numbers were relatively small, the
Mann-Whitney test applied (SigmaStat).
In the same fields on adjacent sections immunostained
with monoclonal anti-phosphorylated tau (AT8), the
numbers of NFTs were counted. Correlations were deter-
mined between the mean level of neuronal prostaglandin
and isoprostane with the number of NFTs in the cases.Molecular Neurodegeneration 2007, 2:2 http://www.molecularneurodegeneration.com/content/2/1/2
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